Optimize Your Dermatology Study With A Data-Informed Protocol Assessment

By Sonja VanWye, RN, MSN, Director of Dermatology Strategy, IQVIA Biotech

How four data-driven protocol design analyses can increase chances of study success in dermatology clinical trials

Nearly 60 percent of clinical trials have protocol amendments,¹ often required to address shortcomings in the study design, endpoints which do not support study objectives, excessive assessments which do not support study endpoints,² or eligibility criteria. Such amendments are a major undertaking, leading to significant timeline delays and additional cost. It is imperative to understand the parts of a clinical trial protocol that could cause potential problems, proactively address them, and maximize the likelihood of study success.